Best Momentum Stocks to Buy for September 24th

Zacks highlighted Red Violet (RDVT), BrightSpring Health Services (BTSG) and Tenet Healthcare (THC) as Zacks Rank #1 momentum stocks. Consensus current-year EPS estimates increased 8.8% for RDVT, 8.3% for BTSG and 14.5% for THC over the past 60 days. The item is positive analyst-driven stock-selection commentary but does not contain company earnings releases or material new corporate disclosures.

Analysis

This is low-information, mechanically generated sell-side momentum content rather than a fundamental catalyst. Estimate-revision signals can attract retail and quant flows over days to weeks, but the reported revisions lack the key underwriting inputs: absolute EPS/EBITDA changes, revenue assumptions, estimate dispersion, and whether revisions follow price rather than lead it. No standalone trade should be initiated from this signal.

Among the three, THC has the clearest liquid institutional transmission mechanism: sustained upward EBITDA revisions could support further multiple resilience if hospital pricing and acuity offset labor inflation. The relevant 1-3 month test is whether consensus EBITDA and free-cash-flow estimates continue rising through the next earnings cycle; a guidance reaffirmation without upward FCF expectations would make a momentum extension vulnerable. Watch HCA and UHS as read-through comparables—sector-wide wage or reimbursement pressure would likely cap THC even if company-specific estimates remain positive.

BTSG's valuation is more sensitive to reimbursement rates, labor availability, and leverage/refinancing costs than to a modest consensus EPS revision. RDVT is the least liquid and therefore most exposed to crowded momentum reversals; its small-cap information-services profile can produce outsized moves, but also makes consensus data less robust. The contrarian view is that estimate-revision screens are most effective when revisions are broadening after an earnings inflection, not when they merely reflect post-report model catch-up.

Key Decisions for Investors

• No immediate position based solely on this article; require independently verified revisions to next-twelve-month EBITDA/FCF, not just EPS, before acting.
• Place THC on a long watch list for a 1-3 month momentum entry only if next-quarter consensus EBITDA rises at least 3% and management raises or tightens full-year cash-flow guidance. Express versus UHS only if THC's revision breadth exceeds UHS's; exit on a THC guidance cut or renewed labor-cost deleverage.
• Avoid chasing BTSG until leverage, reimbursement exposure, and interest-expense sensitivity are reconciled with consensus estimates. A widening in its credit spread or a reimbursement-policy adverse development would invalidate a long setup quickly.
• Treat RDVT as an alert rather than an investable momentum recommendation for larger books: require above-average volume and upward revenue-estimate revisions before considering a small tactical long; use a tight 8-10% risk limit given liquidity and factor-reversal exposure.